Synthesis of dabigatran

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9688657
APP PUB NO 20160060248A1
SERIAL NO

14779911

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl) amino}propanoate and Ethyl-3-{[(2-dichloromethyl-1-methyl-1H-benzimidazole-5-yl)carbonyl]-(2-pyridinyl)amino}propanoate and process for preparation thereof. The present invention further relates to the use of these novel compounds in the preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • USV PRIVATE LIMITED

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Arote, Nitin Dnyaneshwar Mumbai, IN 3 1
Bhopalkar, Rajesh Ganpat Mumbai, IN 2 46
Hagavane, Nitin Nivrutti Mumbai, IN 2 1
Jadhav, Tanaji Shamrao Mumbai, IN 10 32
Mondkar, Harish Kashinath Mumbai, IN 10 104
Patil, Sachin Shivaji Mumbai, IN 2 0
Patkar, Laxmikant Narhari Mumbai, IN 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 27, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00